Oncolytics Biotech Shares Owned By Insiders vs. Current Ratio
| ONC Stock | CAD 1.18 0.02 1.67% |
For Oncolytics Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncolytics Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncolytics Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncolytics Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncolytics Biotech over time as well as its relative position and ranking within its peers.
Oncolytics |
Oncolytics Biotech Current Ratio vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncolytics Biotech's current stock value. Our valuation model uses many indicators to compare Oncolytics Biotech value to that of its competitors to determine the firm's financial worth. Oncolytics Biotech is considered to be number one stock in shares owned by insiders category among its peers. It also is considered to be number one stock in current ratio category among its peers fabricating about 2.31 of Current Ratio per Shares Owned By Insiders. At this time, Oncolytics Biotech's Current Ratio is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Oncolytics Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oncolytics Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Oncolytics Current Ratio vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Oncolytics Biotech |
| = | 3.81 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Oncolytics Biotech |
| = | 8.81 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Oncolytics Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncolytics Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncolytics Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Oncolytics Biotech's change in net profit over the period of time. It can combine multiple indicators of Oncolytics Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 544 K | 516.8 K | |
| Operating Income | -33.8 M | -32.1 M | |
| Net Loss | -27.8 M | -29.1 M | |
| Income Tax Expense | 97 K | 92.2 K | |
| Income Before Tax | -27.7 M | -29 M | |
| Total Other Income Expense Net | 6.1 M | 6.4 M | |
| Net Loss | -27.8 M | -29.1 M | |
| Net Loss | -22.4 M | -23.5 M | |
| Interest Income | 1.3 M | 1.8 M | |
| Net Interest Income | 1.3 M | 1.4 M | |
| Change To Netincome | 801.5 K | 761.5 K | |
| Net Loss | (0.41) | (0.43) | |
| Income Quality | 1.03 | 0.71 | |
| Net Income Per E B T | 1.00 | 0.81 |
Oncolytics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncolytics Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncolytics Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncolytics Biotech's important profitability drivers and their relationship over time.
Use Oncolytics Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.Oncolytics Biotech Pair Trading
Oncolytics Biotech Pair Trading Analysis
The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.
The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Oncolytics Biotech position
In addition to having Oncolytics Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Treasury ETFs Thematic Idea Now
Treasury ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Treasury ETFs theme has 113 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Treasury ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
To fully project Oncolytics Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Oncolytics Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Oncolytics Biotech's income statement, its balance sheet, and the statement of cash flows.